The relevance of tissue angiotensin-converting enzyme: Manifestations in mechanistic and endpoint data

American Journal of Cardiology

Volumn 88, Issue 9 SUPPL. 1, 2001, Pages 1-20

  Dzau, Victor J ^a   Bernstein, Kenneth ^b   Celermajer, David ^c   Cohen, Jerome ^a,d   Dahlöf, Björn ^d   Deanfield, John ^e   Diez, Javier ^f   Drexler, Helmut ^g   Ferrari, Roberto ^h   Van Gilst, Wiek ⁱ   Hansson, Lennart ^j   Hornig, Burkhard ^k   Husain, Ahsan ^l   Johnston, Colin ^m   Lazar, Harold ⁿ   Lonn, Eva ^o   Lüscher, Thomas ^p   Mancini, John ^q   Mimran, Albert ^r   Pepine, Carl ^s   Rabelink, Ton ^t   Remme, Willem ^u   Ruilope, Luis ^v   Ruzicka, Marcel ^w   Schunkert, Heribert ^x   Swedberg, Karl ^e   Unger, Thomas ^y   Vaughan, Douglas ^z   Weber, Michael ^aa   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^g UNIVERSITY OF NAVARRA   (Spain)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ Department of Clinical Pharmacology ^*  (Italy)

^j UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^k UPPSALA UNIVERSITY   (Sweden)

^l VICTOR CHANG CARDIAC RESEARCH INSTITUTE   (Australia)

^m BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

ⁿ BOSTON MEDICAL CENTER   (United States)

^o HAMILTON GENERAL HOSPITAL   (Canada)

^p UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^q VANCOUVER GENERAL HOSPITAL   (Canada)

^r LAPEYRONIE HOSPITAL   (France)

^s UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^t UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^u Sticares Cardiovascular Research Foundation   (Netherlands)

^v Hospital La Paz   (Spain)

^w UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^x Klinik und Poliklinik für Innere Medizin II Universitätsklinikum Halle   (Germany)

^y UNIVERSITY OF KIEL   (Germany)

^z VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^aa BROOKDALE UNIVERSITY HOSPITAL AND MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; BENAZEPRILAT; BRADYKININ; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; FOSINOPRILAT; HYDRALAZINE PLUS ISOSORBIDE; LISINOPRIL; PERINDOPRILAT; PLACEBO; QUINAPRIL; QUINAPRILAT; RAMIPRIL; RAMIPRILAT; TRANDOLAPRIL; UNCLASSIFIED DRUG; ZOFENOPRIL;

CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG BINDING; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENCY; DRUG SOLUBILITY; ENDOTHELIUM; ENDOTHELIUM LESION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LOCALIZATION; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATORY CELL; KIDNEY DISEASE; PARENCHYMA; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0035834247     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(01)01878-1     Document Type: Article

References (160)

1. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors
2. Comparative properties of angiotensin-converting enzyme inhibitors: Relations with inhibition of tissue angiotensin-converting enzyme and potential clinical implications
3. Concentrations of angiotensin-converting enzyme in tissues of the rat
4. The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice
5. Genetic mapping of a gene causing hypertension in the stroke-prone spontaneously hypertensive rat
6. Heart mass and blood pressure have separate genetic determinants in the New Zealand genetically hypertensive (GH) rat
7. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels
8. Angiotensin-converting enzyme in the human heart: Effect of the deletion/insertion polymorphism
9. Polymorphism of the angiotensin-converting enzyme gene and cardiovascular disease
10. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction
11. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy
12. ACE gene polymorphism and cardiovascular diseases
13. DD genotype of the angiotensin-converting enzyme gene is a risk factor for left ventricular hypertrophy
14. Long-term effect of ACE inhibition on development of nephropathy in diabetes mellitus type II
15. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease
16. Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass
17. Controversial association of left ventricular hypertrophy and the ACE I/D polymorphism: Is the mist clearing up?
18. Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training
19. Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction: Captopril and Thrombolysis Study Investigators
20. Genetic basis of left ventricular remodeling after myocardial infarction
21. Cardiovascular end-organ damage in Ren-2 transgenic rats compared to spontaneously hypertensive rats
22. Context-dependent associations of the ACE I/D polymorphism with blood pressure
23. Angiotensin I-converting enzyme gene polymorphism, coronary artery disease and myocardial infarction: An angiographically controlled study
24. Fate of angiotensin I in the circulation
25. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy: Effects on coronary resistance, contractility, and relaxation
26. Localization of angiotensin converting enzyme in rat heart
27. Cellular distribution of angiotensin-converting enzyme after myocardial infarction
28. Effects of ACE inhibitors on circulating versus cardiac angiotensin II in volume overload-induced cardiac hypertrophy in rats
29. Expression of renin-angiotensin system components in the heart, kidneys, and lungs of rats with experimental heart failure
30. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure
31. Increased cardiac angiotensin-converting enzyme in rats with chronic heart failure
32. Expression of angiotensin-converting enzyme in remaining viable myocytes of human ventricles after myocardial infarction
33. Activation of angiotensinogen and angiotensin-converting enzyme gene expression in the left ventricle of senescent rats
34. Local stress, not systemic factors, regulate gene expression of the cardiac renin-angiotensin system in vivo: A comprehensive study of all its components in the dog
35. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro
36. Is there an internal cardiac renin-angiotensin system?
37. Chymase does not contribute to angiotensin I-II conversion in the interstitial fluid
38. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart
39. Reciprocal regulation of pulmonary and cardiac angiotensin-converting enzyme in rats with severe left ventricular hypertrophy
40. Aspects of molecular biology and biochemistry of the cardiac renin-angiotensin system
41. Angiotensin production by the heart: A quantitative study in pigs with the use of radiolabeled angiotensin infusions
42. Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts: Evidence for renin binding
43. Uptake of renin and prorenin by the isolated rat heart
44. Expression and localization of renin and angiotensinogen in rat heart after myocardial infarction
45. Selective activation of cardiac angiotensinogen gene expression in post-infarction ventricular remodeling in the rat
46. 1 receptor in the human isolated coronary artery
47. Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts
48. Angiotensin II formation in the intact human heart: Predominance of the angiotensin-converting enzyme pathway
49. Vascular angiotensin-converting enzyme expression regulates local angiotensin II
50. Angiotensin II-forming pathways in normal and failing human hearts
51. Local angiotensin II generation in the rat heart: Role of renin uptake
52. Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid: Inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin-converting enzyme by Ang-(1-9) formed by heart carboxypeptidase A-like activity
53. ACE knockout mice: Lessons for adult nephrology
54. Angiotensin I and II exert inotropic effects in atrial but not in ventricular human myocardium: An in vitro study under physiological experimental conditions
55. Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility
56. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells
57. Angiotensin II-induced growth responses in isolated adult rat hearts: Evidence for load-independent induction of cardiac protein synthesis by angiotensin II
58. Effects of long-term angiotensin converting enzyme inhibition on myocardial hypertrophy in experimental aortic stenosis in the rat
59. Blockade of the renin-angiotensin system in cardiac pressure-overload hypertrophy in rats
60. ACE inhibitors and cardiac ACE mRNA in volume overload-induced cardiac hypertrophy
61. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats
62. Pathological hypertrophy and cardiac interstitium: Fibrosis and renin-angiotensin-aldosterone system
63. Cultured myofibroblasts generate angiotensin peptides de novo
64. Regulation of extracellular matrix proteins in pressure-overload cardiac hypertrophy: Effects of angiotensin converting enzyme inhibition
65. Quinapril decreases myocardial accumulation of extracellular matrix components in spontaneously hypertensive rats
66. Communication between myocytes and fibroblasts in cardiac remodeling in angiotensin chimeric mice
67. Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell
68. p53 Induces myocyte apoptosis via the activation of the renin-angiotensin system
69. Cardiomyocyte apoptosis and cardiac angiotensin-converting enzyme in spontaneously hypertensive rats
70. Intracardiac angiotensin-converting enzyme inhibition improves diastolic function in patients with left ventricular hypertrophy due to aortic stenosis
71. Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis
72. Exacerbation of left ventricular ischemic diastolic dysfunction by pressure-overload hypertrophy: Modification by specific inhibition of cardiac angiotensin converting enzyme
73. Direct myocardial and coronary effects of enalaprilat in patients with dilated cardiomyopathy: Assessment by a bilateral intracoronary infusion technique
74. Effects of quinapril, a new angiotensin converting enzyme inhibitor, on left ventricular failure and survival in the cardiomyopathic hamster: Hemodynamic, morphological, and biochemical correlates
75. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
76. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
77. The angiotensin I-converting enzyme
78. Glucocorticoids induce angiotensin-converting enzyme expression in vascular smooth muscle
79. Bovine angiotensin converting enzyme cDNA cloning and regulation. Increased expression during endothelial cell growth arrest
80. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects
81. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans
82. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1
83. Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options
84. Endothelial dysfunction in human disease
85. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: Contribution to alterations of vasomotor tone
86. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease
87. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice
88. Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease
89. Glomerular hemodynamic changes vs. hypertrophy in experimental glomerular sclerosis
90. Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells
91. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis
92. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects
93. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy
94. Control of hypertension with the angiotensin converting enzyme inhibitor captopril reduces glomerular proteinuria
95. Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis
96. Additive antiproteinuric effect of ACE inhibition and a low-protein diet in human renal disease
97. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
98. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
99. Antihypertensive therapy in type 2 diabetes: Implications of the appropriate blood pressure control in diabetes (ABCD) trial
100. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study
101. Systolic blood pressure as a predictor for cardiovascular disease in diabetes: A 5-year longitudinal study
102. NIDDM and its metabolic control predict coronary heart disease in elderly subjects
103. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy : Collaborative Study Group
104. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
105. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency
106. Renin and angiotensin
107. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
108. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction: Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators
109. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients
110. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure: Collaborative Group on ACE Inhibitor Trials
111. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
112. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial: SAVE Investigators
113. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction: TRACE Study Group Trandolapril Cardiac Evaluation
114. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100,000 patients in randomized trials
115. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4
116. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction
117. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions
118. Effects of captopril on ischemic events after myocardial infarction: Results of the Survival and Ventricular Enlargement trial
119. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection
120. The QUinapril Ischemic Event Trial (QUIET) design and methods: Evaluation of chronic ACE inhibitor therapy after coronary artery intervention
121. Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: No answer yet
122. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: Heart Outcomes Prevention Evaluation Study Investigators
123. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: The TREND (Trial on Reversing Endothelial Dysfunction) Study
124. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study)
125. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction: HEART Study Investigators
126. Angiotensin II formation in human vasculature after chronic ACE inhibition: A prospective, randomized, placebo-controlled study
127. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design): Prevention of Events with Angiotensin-Converting Enzyme Inhibition
128. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA)
129. EUROPA substudies, confirmation of pathophysiological concepts: European trial on reduction of cardiac events with perindopril in stable coronary artery disease
130. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction
131. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril coronary atherosclerosis trial (SCAT)
132. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease
133. Effects of ramipril and vitamin E on atherosclerosis: The study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE)
134. Results of the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE)
135. Converting enzyme inhibitors in cardiovascular therapy: Current status and future potential
136. Structural constraints of inhibitors for binding at two active sites on somatic angiotensin converting enzyme
137. Characterization of cardiac angiotensin converting enzyme (ACE) and in vivo inhibition following oral quinapril to rats
138. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors
139. The cardiac renin-angiotensin system in heart failure
140. Measurement of angiotensin I converting enzyme inhibition in the heart
141. Inhibition of angiotensin-converting enzyme (ACE) in plasma and tissue
142. ACE Inhibitors: Specific agents and pharmacokinetics
143. Functional importance of angiotensin-converting enzyme-dependent in situ angiotensin II generation in the human forearm
144. Angiotensin-converting enzyme-independent contraction to angiotensin I in human resistance arteries
145. Effect of enalaprilat on nitric oxide activity in coronary artery disease
146. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure
147. Effect of enalapril and quinapril on forearm vascular ACE in man
148. Ramipril prevents endothelial dysfunction induced by oxidized low-density lipoproteins: A bradykinin-dependent mechanism
149. Ramiprilat prevents the development of acute coronary endothelial dysfunction in the dog
150. Peripheral artery structure and endothelial function in heart failure: Effect of ACE inhibition
151. ACE inhibition accelerates endothelial regrowth in vivo: A possible explanation for the benefit observed with ACE inhibitors following arterial injury
152. Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease
153. Endothelial function and oxidant stress
154. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: Evidence for involvement of the renin-angiotensin system
155. Mechanism by which quinapril improves vascular function in coronary artery disease
156. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus
157. Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo
158. Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling
159. Angiotensin-converting enzyme inhibitors